Prostate cancer gene therapy

F. A. Ferrer, R. Rodriguez

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Cancer-specific gene therapy is still in its infancy. Although the first gene therapy trials were initiated in the late 1980s, it was only more recently that the first successful treatment of a genetic disease was reported. The current problems with low efficiency of gene transfer coupled with the immunologic difficulties with certain vectors indicate that more effort needs to be directed at the basic science of gene transfer. Ultimately, successful camcer-specific gene therapy will require combinations of the lessons learned from the ex vivo and in vivo paradigms. The next generation of gene therapy trials likely will focus on combination therapy with conventional chemotherapeutic agents, differentiating agents, or radiation theraphy. The obstacle to the development of gene-based human therapeutic (i.e., molecular medicine) are formidable, but the benefits are so great that eventually the technical issues of gene transfer methodology will be worked out, and ultimately this will become the standard of care, not only for inborn errors of metabolism, but also for cancer.

Original languageEnglish (US)
Pages (from-to)497-508
Number of pages12
JournalHematology/Oncology Clinics of North America
Issue number3
StatePublished - Jan 1 2001
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Prostate cancer gene therapy'. Together they form a unique fingerprint.

Cite this